XWPharma
Shanghai, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
Clinical-stage CNS biotech developing novel small molecules for narcolepsy, Parkinson's disease sleep disorders, depression, and chronic pain using time-regulated neurobiology.
NeuroscienceImmunology
Technology Platform
Proprietary drug discovery methodology applying novel platform chemistry to time-regulated neurobiology, focusing on clinically validated mechanisms of action to create new chemical entities with strong IP protection.
Opportunities
Large addressable markets in narcolepsy (orphan disease with $2B existing market), treatment-resistant depression, and chronic pain with significant unmet needs; potential for first FDA-approved treatment for Parkinson's disease sleep disorders.
Risk Factors
Clinical-stage company with no approved products; CNS drug development has high failure rates; competition from existing GABA-B agonists and ketamine/esketamine therapies; dependence on clinical validation of time-regulated neurobiology approach.
Competitive Landscape
In narcolepsy, competes with Jazz Pharmaceuticals' Xyrem/Xywav (GABA-B agonists); in depression/pain, faces competition from Spravato (esketamine) and generic ketamine; differentiation through oral once-daily dosing and novel time-regulated neurobiology approach.